期刊文献+

甲氨蝶呤、阿糖胞苷鞘内注射严重不良反应分析 被引量:4

Analysis of Serious Adverse Reactions of the Nervous System Induced by Methotrexate and Cytarabine Intrathecal Injection
下载PDF
导出
摘要 目的:了解鞘内化疗致严重不良事件的现状,为防范严重不良反应(SADRs)的发生、实施风险管理措施提供依据,探讨发生机制。方法:汇总国内近13年有关鞘内注射甲氨蝶呤(Methotrexate,MTX)和(或)阿糖胞苷(Cytarabine,Ara-C)注射液引起严重神经系统损伤70例以及我院4例,进行统计分析。结果:在74例中,由单独鞘注MTX引起者64.0%,单独鞘注ara-C引起者6.0%,两药合并鞘注引起者30.0%。SADRs的主要表现类型:急性化学性脊神经根炎(63.5%),急性化学脑膜炎(23.0%),白质脑病(2.7%)和视神经炎(4.1%)。81%患者出现SADRs症状在数小时或数天后消失,6.8%患者有后遗症状,12.2%预后差。结论:多种机制作用下发生不良事件。鞘内注射MTX或ara-C均可导致SADRs,以MTX致SADRs的发生率高,提倡规范操作,加强药品安全监管措施,可降低SADRs的发生率。 Objective: To understand the present situation of serious adverse events with intrathecal chemotherapy and provide some gists for preventing the occurrence of serious adverse reactions (SADRs) and implementing some risk management measures for this occurrence. This essay also tried to explore the mechanism of SARs. Method: 4 cases in our hospital and 70 other cases in China, which caused serious neurological damages during the last 13 year by injecting intrathecal methotrexate (MTX) and (or) cytarabine, were collected and statistically analyzed. Result: 64% of 74 eases were caused by injecting MTX alone, 6% was caused by injecting intrathecal Arac alone and 30% was caused by injecting these two drugs once. Here came the main types of performance of SADRs : acute chemical inflammation of the spinal nerve root (63.5%) , acute chemical meningitis (23.0%) , leukoencephalopathy (2.7%) , and optic neuritis (4.1%). Symptoms of SADRs in 81% of the patients disappeared in several hours or days following the injections, 6.8% of the patients had their sequels, and 12.2% had their poor prognosis. Conclusion: Many adverse events are caused by a variety of mechanisms. Injecting intrathecal methotrexate or ara-C can lead to SADRs, but the MTX injection has the highest rate of occurrence. Therefore, some standardized operations and drug safety monitoring measures should be promoted and strengthened. Only by doing these things could the occurrences of SADRs can be reduced.
出处 《药物流行病学杂志》 CAS 2008年第6期381-383,共3页 Chinese Journal of Pharmacoepidemiology
关键词 鞘内注射 甲氨蝶呤 阿糖胞苷 药物不良反应 机制 Intrathecal Methotrexate Cytarabine Adverse drug reactions Mechanism
  • 相关文献

参考文献12

  • 1Bleyer WA, Drake JC, Chabner BA. Pharmacokinetics of nimustine, methotrexate, and cytosine arabinoside during cerebrospinal fluid perfusion chemotherapy in patients with disseminated brain tumors [ J ]. European Clinical Pharmacology, 1998,5 (4) :415-420.
  • 2Gagliano RG, Costanzi JJ. Paraplegia following intrathecal cytosine arabinosid [ J ]. Cancer, 1976,37 (4) : 1663-1668.
  • 3Rubinstein LJ, Rawlinson DG, Herman MM,et al. Disseminated necrofizing leukoencephalopothy complication of treated central [J]. Cancer, 1982,50( 1 ) :42-47.
  • 4Mcintosh S, Cohen SR, Nissenblatt M J, et al. Paraplegia following intrathecal chemotherapy: neuropathologic findings and elevation of myelin basic protein [ J ]. Cancer, 1975,3 (5) :291.
  • 5Jacobs AD, Nann WW, Bacher WP, et al. Recent advances in the biologyand treatment of acute Lymphoblastic Leuckemiu in adults [J]. Cancer,1984,31 (19):1219.
  • 6Buck EH. Death after intratheca methotrexate [ J ]. Lancet, 1969,2 (7632) :1005.
  • 7刘成立.鞘内注射氨甲喋呤引起脊神经根病死亡1例.白血病.淋巴瘤,2000,(6):337-337.
  • 8于亦奎 陈风滨.ara-C鞘内注射致截瘫、肺水肿1例.中国实用内科杂志,1995,15(5):313-313.
  • 9唐莉华.甲氨蝶呤鞘内注射致非药源性不良反应2例[J].广东医学,2005,26(1):43-43. 被引量:1
  • 10Geiser C , Fdedrick RL. Clinical pharmacology of interecal methotrexate [ J]. Cancer, 1975,35 (41) :306.

共引文献1

同被引文献27

  • 1杨享贤,陈海林,林远雄.23例髓母细胞瘤术后放疗的疗效观察[J].中华放射肿瘤学杂志,2006,15(6):494-495. 被引量:2
  • 2于亦奎 陈风滨.ara-C鞘内注射致截瘫、肺水肿1例.中国实用内科杂志,1995,15(5):313-313.
  • 3孙燕,周际昌.临床肿瘤内科手册.4版.北京:人民卫生出版社,2004:106-107.
  • 4David KM, Casey AT, Hayward RD, Harkness WF, Phipps K,Wade AM. Medulloblastoma: is the 5 - year survival rateimproving. A review of 80 cases from a single institution. JNeurosurg, 1997, 86:13-21.
  • 5Wendland MM, Shrieve DC, Watson GA, Chin SS, BlumenthalDT. Extraneural metastatic medulloblastoma in an adult. JNeurooncol, 2006, 78:191-196.
  • 6Sarkar C, Pramanik P, Karak AK, Mukhopadhyay P, SharmaMC, Singh VP, Mehta VS. Are childhood and adultmedulloblastomas different: a comparative study ofclinicopathological features, proliferation index and apoptoticindex. J Neurooncol, 2002, 59:49-61.
  • 7Meyers SP, Wildenhain SL, Chang JK, Bourekas EC, BeattiePF, Korones DN, Davis D, Pollack IF, Zimmerman RA.Postoperative evaluation for disseminated medulloblastomainvolving the spine: contrast enhanced MR findings, CSFcytologic analysis, timing of disease occurrence, and patientoutcomes. AJNR Am J Neuroradiol, 2000, 21:1757-1765.
  • 8Phi JH, Lee J, Wang KC, Cho BK, Kim IO, Park CK, Kim CY,Ahn HS, Kim IH, Kim SK. Cerebrospinal fluid M staging formedulloblastoma: reappraisal of Chang's M staging based on theCSF flow. Neuro Oncol, 2011,13:334-344.
  • 9Nazmy M, Khafaga Y, A1 Hebshi A, Hassounsh M, Albadawy S.Adult medulloblastoma: a single institution experience. Gulf JOncolog, 2014, 1:27-31.
  • 10Herrlinger U, Steinbrecher A, Rieger J, Hau P, Kortmann RD,Meyermann R, Schabet M, Bamberg M, Dichgans J, Bogdahn U,Weller M. Adult medulloblastoma prognostic factors andresponse to therapy at diagnosis and at relapse. J Neurol, 2005,252:291-299.

引证文献4

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部